Canaccord analyst Edward Nash downgraded Pliant Therapeutics (PLRX) to Hold from Buy with a price target of $4, down from $43, after the company paused enrollment and dosing in the ongoing Phase 2b BEACON-IPF clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis following recommendations by the data safety monitoring board.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Maintaining a Buy Rating on Pliant Therapeutics Despite Bexotegrast Trial Pause and Market Overreaction
- Pliant Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Pliant Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Pliant Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Pliant Therapeutics downgraded to Neutral from Buy at Citi